Vimarsana
Biggest News Aggregation in the World

Page 7 - Steve Bernstein News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Steve Bernstein. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Steve Bernstein Today - Breaking & Trending Today

Phase 1 Trial of SC-DARIC33 in Pediatric R/R CD33+ AML on Hold After Serious Grade 5 AE - Vimarsana News

Phase 1 Trial of SC-DARIC33 in Pediatric R/R CD33+ AML on Hold After Serious Grade 5 AE

The phase 1 PLAT-08 trial investigating SC-DARIC33 in pediatric and young-adult patients with relapsed/refractory CD33-positive acute myeloid leukemia has been paused following the report of a grade 5 serious adverse effect.

Patient Death Leads to Pause in Test of 2seventy Bio Cell Therapy for Leukemia - Vimarsana News

Patient Death Leads to Pause in Test of 2seventy Bio Cell Therapy for Leukemia

2seventy Bio reported that an acute myeloid leukemia patient treated with its experimental cell therapy has died, prompting research partner Seattle Children’s Research Institute to pause the Phase 1 study. The FDA has been notified and an investigation is underway.

Pink Floyd's New LP Is Top Of The Pre-Order List - Vimarsana News

Pink Floyd's New LP Is Top Of The Pre-Order List

Pink Floyd have knocked the manufactured boy band, One Direction, off the top of the most pre-ordered album list.

Source: nova.ie
2seventy bio, Inc.: 2seventy bio Announces Additional Data from KarMMa Studies of Abecma (idecabtagene vicleucel) at ASCO 2023 and EHA 2023 - Vimarsana News

2seventy bio, Inc.: 2seventy bio Announces Additional Data from KarMMa Studies of Abecma (idecabtagene vicleucel) at ASCO 2023 and EHA 2023

Subgroup analysis of outcomes for patients with high-risk relapsed and refractory multiple myeloma (RRMM) from the pivotal Phase 3 KarMMa-3 trial accepted for oral presentation at EHA Analysis from

2seventy bio Announces Additional Data from KarMMa Studies of Abecma (idecabtagene vicleucel) at ASCO 2023 and EHA 2023 - Vimarsana News

2seventy bio Announces Additional Data from KarMMa Studies of Abecma (idecabtagene vicleucel) at ASCO 2023 and EHA 2023

Subgroup analysis of outcomes for patients with high-risk relapsed and refractory multiple myeloma from the pivotal Phase 3 KarMMa-3 trial accepted for oral presentation at EHA Analysis from... | May 11, 2023